Evidence map›Paper›PMID 26338901›Full record

ArticleCirculation research2015

Dual Labeling Biotin Switch Assay to Reduce Bias Derived From Different Cysteine Subpopulations: A Method to Maximize S-Nitrosylation Detection.

Heaseung Sophia Chung, Christopher I Murray, Vidya Venkatraman, Erin L Crowgey, Peter P Rainer, Robert N Cole, Ryan D Bomgarden, John C Rogers, Wayne Balkan, Joshua M Hare and 2 more

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Cysteine-S-nitrosylation inhibits Rop5-mediated immune evasion inbioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Proteomics of the heart.Physiological reviews · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Biological Mechanisms ofAntioxidants (Basel, Switzerland) · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Heaseung Sophia ChungFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Christopher I MurrayFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Vidya VenkatramanFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Erin L CrowgeyFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Peter P RainerFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Robert N ColeFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Ryan D BomgardenFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
John C RogersFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Wayne BalkanFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Joshua M HareFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
David A KassFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.).
Jennifer E Van EykFrom the Department of Biological Chemistry (H.S.C., C.I.M., R.N.C., J.E.V.E.), Division of Cardiology, Department of Medicine (V.V., P.P.R., D.A.K., J.E.V.E.), The Johns Hopkins NHLBI Proteomics Innovation Center on Heart Failure (H.S.C., V.V., D.A.K., J.E.V.E.), Department of Medicine, Mass Spectrometry and Proteomic Core Facility (R.N.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Thermo Fisher Scientific, Rockford, IL (R.D.B., J.C.R.); Advanced Clinical Biosystems Research Institute, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (V.V., E.L.C., J.E.V.E.); Department of Medicine, Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, FL (W.B., J.M.H.); Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada (C.I.M.); and Division of Cardiology, Medical University of Graz, Austria (P.P.R.). Jennifer.VanEyk@cshs.org.
University of British Columbia · CACedars-Sinai Medical Center · USThermo Fisher Scientific (United States) · USUniversity of Miami · US

Funding

Pathobiology of Cardiac Dyssynchrony &ResynchronizationP01HL077180 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI VAN EYK, JENNIFER E · 2004 to 2014
$22.8M
Shared Resource CoresP01HL107153 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2011 to 2017
$16.8M
Protein Chemistry and ProteomicsP01HL112730 · NHLBI · SAN DIEGO STATE UNIVERSITY · PI VAN EYK, JENNIFER E · 2013 to 2017
$12.0M
MItochondrial Dysfunction in Cardiac Hypertrophy and FailureR01HL101235 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BERS, DONALD M, BLATTER, LOTHAR A · 2010 to 2013
$2.8M
PKG Redox Modulation of Cardiac Function and DiseaseR01HL119012 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2013 to 2016
$1.6M
NHLBI NIH HHS 1P01HL112730-01A1NHLBI NIH HHS NHLBI-HV-05(2)NHLBI NIH HHS P01 HL077180NHLBI NIH HHS P01 HL10026NHLBI NIH HHS P01 HL107153NHLBI NIH HHS P01 HL112730NHLBI NIH HHS P01HL77189-01NHLBI NIH HHS R01 HL101235NHLBI NIH HHS R01 HL119012NHLBI NIH HHS R01HL119012
6 · The paper itself

Abstract

rationaleS-nitrosylation (SNO), an oxidative post-translational modification of cysteine residues, responds to changes in the cardiac redox-environment. Classic biotin-switch assay and its derivatives are the most common methods used for detecting SNO. In this approach, the labile SNO group is selectively replaced with a single stable tag. To date, a variety of thiol-reactive tags have been introduced. However, these methods have not produced a consistent data set, which suggests an incomplete capture by a single tag and potentially the presence of different cysteine subpopulations.

objectiveTo investigate potential labeling bias in the existing methods with a single tag to detect SNO, explore if there are distinct cysteine subpopulations, and then, develop a strategy to maximize the coverage of SNO proteome. METHODS AND

resultsWe obtained SNO-modified cysteine data sets for wild-type and S-nitrosoglutathione reductase knockout mouse hearts (S-nitrosoglutathione reductase is a negative regulator of S-nitrosoglutathione production) and nitric oxide-induced human embryonic kidney cell using 2 labeling reagents: the cysteine-reactive pyridyldithiol and iodoacetyl based tandem mass tags. Comparison revealed that <30% of the SNO-modified residues were detected by both tags, whereas the remaining SNO sites were only labeled by 1 reagent. Characterization of the 2 distinct subpopulations of SNO residues indicated that pyridyldithiol reagent preferentially labels cysteine residues that are more basic and hydrophobic. On the basis of this observation, we proposed a parallel dual-labeling strategy followed by an optimized proteomics workflow. This enabled the profiling of 493 SNO sites in S-nitrosoglutathione reductase knockout hearts.

conclusionsUsing a protocol comprising 2 tags for dual-labeling maximizes overall detection of SNO by reducing the previously unrecognized labeling bias derived from different cysteine subpopulations.

Indexed as

Molecular ProbesAlcohol DehydrogenaseAnimalsBiotinCysteineFemaleHEK293 CellsHumansMaleMice, Inbred C57BLMice, KnockoutMyocardiumNitrosationNitroso CompoundsProtein Processing, Post-TranslationalProteomicsAdh5 protein, mouseAlcohol DehydrogenaseBiotinCysteineMolecular ProbesNitroso Compoundsnitric oxideoxidation-reductionproteomicsS-nitrosothiols

Identifiers

PMID26338901
PMCPMC4979977
OpenAlexW1793434462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.